GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Mohammad Hossein Noyan-Ashraf,1 M. Abdul Momen,1 Kiwon Ban,1,6 Al-Muktafi Sadi,1 Yu-Qing Zhou,2 Ali M. Riazi,2 Laurie L. Baggio,3 R. Mark Henkelman,2 Mansoor Husain,1,4,5,8 and Daniel J. Drucker2,5

OBJECTIVE—Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear.

RESEARCH DESIGN AND METHODS—We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide.

RESULTS—Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%; P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSKβ, PPARβ, Nrf2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R-dependent manner in vitro.

CONCLUSIONS—These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo. Diabetes 58:975–983, 2009

The protection against ischemic damage provided by cycling periods of ischemia and reperfusion, that is, ischemic preconditioning (IP), may last for hours or even days (1). Although the molecular basis of ischemic preconditioning is complex and incompletely understood, there is active interest in the development of therapeutic interventions that protect the myocardium against ischemic injury.

Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies. A functional GLP-1 receptor (GLP-1R) is expressed in the heart (3), and GLP-1R agonists directly activate cardiomyocyte signaling pathways (4). Because the GLP-1R is also expressed in the endocrine pancreas, GLP-1 may regulate cardiac function indirectly through metabolic control of glucose, insulin, glucagon, and free fatty acids. Furthermore, GLP-1R agonists activate the peripheral and central nervous system (CNS), including regions of the CNS important for control of cardiovascular function (5–7). The mechanisms through which GLP-1 can modulate cardiac function are complex and incompletely understood.

Transient GLP-1 administration improves outcomes in experimental models of cardiac injury such as pacing-induced heart failure (8) and experimental ischemia induced by coronary ligation (9–13). A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14). Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).

Although the glucoregulatory actions of the first clinically approved GLP-1R agonist, exenatide, have been extensively studied in the clinic (2), there is limited information available about the effects of exenatide on the normal or ischemic heart (16). A second GLP-1R agonist, liraglutide, is a human dipeptidyl peptidase-4 (DPP-4)-resistant GLP-1 analog that exhibits a prolonged pharmacokinetic profile, relative to native GLP-1, resulting from noncovalent association with albumin (2,17,18), and has completed phase 3 clinical trials in human subjects with type 2 diabetes. Although liraglutide appears to be a promis-
ing antidiabetic agent (19), the effects of iraglutide on the cardiovascular system have not been examined. We have now assessed whether iraglutide exerts cardioprotective actions in a preclinical murine model of experimental ischemia after coronary artery occlusion. We show that treatment with iraglutide before induction of ischemia leads to activation of prosurvival kinases and cytoprotective genes in the heart and limits infarct size, expansion, and cardiac rupture in the normal and diabetic heart. Moreover, iraglutide increases cAMP and reduces apoptosis in a GLP-1R–dependent manner in murine cardiomyocytes cultured in vitro. These findings extend our understanding of the cardioprotective actions of GLP-1R agonists and provide testable hypotheses for examining the cardiovascular effects of GLP-1R agonists in human subjects with type 2 diabetes.

RESEARCH DESIGN AND METHODS

Animals. Protocols were approved by the Animal Care Committee of the Toronto General Hospital in accordance with guidelines of the Canadian Council for Animal Care. Male 10- to 12-week-old C57BL6/J mice were obtained from Charles River (Montreal, PQ, Canada) and housed for at least 2 weeks before experimentation.

Drug treatments. The volume of individual i.p. injections was 100 μL. The experimental protocols are summarized in supplemental Fig. 1 (available in an online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db08-1193). One group of animals (n = 75) was injected with the GLP-1R agonist iraglutide (Novo Nordisk, Novo Alle, Bagsvaerd, Denmark) at a previously used dose of 200 μg/kg i.p. twice daily (18) for 7 days before permanent surgical ligation of the left anterior descending (LAD) artery as previously detailed (20). A parallel group of control animals (n = 75) was injected with an equivalent volume of the vehicle, PBS. After this treatment period, some animals (n = 10 per group) were killed just before planned LAD ligation. Hearts dissected immediately, weighed, and frozen. A second group of mice received PBS or iraglutide (n = 10 each) for 7 days and were subjected to sham surgery without LAD occlusion. Because a regimen of iraglutide 200 μg/kg i.p. twice daily (LIR 200) induced weight loss in mice, we also studied the effects of LAD ligation in separate groups of mice after administration of a lower dose of iraglutide (75 μg/kg i.p. twice daily; LIR 75) that did not produce significant weight loss or pair-feeding to induce weight loss in control animals comparable to that seen in mice treated with LIR 200. Separate groups of PBS- and iraglutide-treated mice (n = 43 per group) were killed on day 4 post-mycocardial infarction (MI) for biochemical and histological analyses. LV tissues from infarct and peri-infarct zones and remote (noninfarced) area were separated, snap-frozen, and stored at −80°C. The remaining mice were monitored for 28 days post-MI for survival analysis and histomorphometry for infarct size and in separate studies, mice were maintained on a high-fat diet (45% Kcal from fat; D-12451; Research Diets) for 1 month, following which diabetes was induced by treatment with streptozotocin (90 μg/kg i.p.). After stratification by degree of hyperglycemia at 3 weeks after streptozotocin injection, mice were randomized to receive treatment for 7 days with placebo (PBS, 100 μL i.p. twice daily), metformin in chow (6.76 g/kg of mouse diet), or iraglutide 75 μg twice daily (LIR 75) before sham or LAD-ligation surgery (n = 23/group: sham, 8 LAD-ligation). Diabetic mice were maintained on the high-fat diet until the day of surgery. Postoperative care included the known GLP-1R agonist in the cardiac actions of iraglutide, male GPlpr–/– mice, 10 to 12 weeks of age, in the C57BL6 background and their littermates (GPlpr+/–) controls (n = 4/group), were injected with either PBS or 75 μg iraglutide twice daily for 1 week, then killed and their hearts used for Western blot assessment of prosurvival kinases.

Neocaps. Cardiac examinations were performed on deceased mice post-MI. The amount of infarcted myocardial tissue of the heart and the thoracic cavity as well as a perfusion of the infarct or peri-infarct area was taken to indicate cardiac rupture.

Blood glucose. Before anesthesia, nonfasting blood glucose measurements were obtained through a tail nick using a handheld glucometer and One-Touch glucometer strips (LifeScan Canada, Burnaby, BC, Canada).

Cardiac hypertrophy. Heart-to-body weight ratios were calculated for each animal at the time of terminal euthanasia.

Infarct size. Demarcation of the infarct area was performed in separate groups of PBS- and iraglutide-treated mice using either 2,3,5-triphenyl tetrazolium chloride (TTC) or hematoxylin and eosin (H-E) staining at 2 and 28 days post-MI, respectively, as described (20, 21). Sections from three levels of each heart (5 μm: apical, midventricular, and basal) were stained with H-E and scanned, and the circumference of the fibrotic infarct area and entire left ventricle was measured with Image J software (NIH). The mean of measurements of percent infarct size (circumference) was then calculated (infarct circumference/total LV circumference × 100%).

For analysis after TTC staining, hearts were sectioned perpendicular to the long axis with a thickness of ~2 mm from the apical, midventricular, and basal (immediately below the ligation point) regions and incubated in the prewarmed (30°C) fresh TTC solution for 15 min. They were then weighed and transferred to a 4% paraformaldehyde solution for 1 h before image acquisition with a digital camera. Infarct and total left ventricle areas were then measured by Image J for determination of percent infarct size (area) by calculation (infarct area/total LV area × 100%).

Zymography. Matrix metalloproteinase-9 (MMP-9) was assessed in the infarct zone 4 days post-MI as described (22).

Cell culture, cAMP assay, and tumor necrosis factor-α–induced apoptosis. Cardiomyocytes from newborn mice were prepared using a modified protocol (23). For cAMP assay, neonatal mouse cardiac myocytes were preincubated with IBMX (250 μmol/L; Sigma) for 30 min to inhibit cAMP degradation followed by subsequent treatment periods of 20 min for iraglutide (100 μmol/L), 30 min for the GLP-1R antagonist exendin (Exy)3-9 (1 μmol/L), and 15 min for forskolin (100 nmol/L). For the iraglutide + Exy3-9 treatment, cells were exposed to Exy3-9 for 30 min before coincubation with fresh Exy3-9 and iraglutide for an additional 20 min. All experiments were performed in quadruplicate. Samples were collected and analyzed using a cAMP radioimmunoassay kit (Amersham, Little Chalfont, UK). For tumor necrosis factor-α (TNF-α) experiments, cells were grown on six-well dishes, serum deprived for 24 h, incubated for 1 h with 10,100, or 1,000 μmol/L iraglutide (Gel Code) or the GLP-1R antagonists for 24 h. Cells were then cooled to 4°C and stimulated for 24 h with iraglutide and TNF-α (100 ng/mL; Sigma) for another 24 h to induce apoptosis (24). As a positive control for the induction of apoptosis, another group of cardiomyocytes was exposed to 0.5 μmol/L H2O2, as described (25). All experiments were performed in triplicate. Western blot analysis using whole cell extracts was used to quantify levels of cleaved caspase 3.

Western blot. Extracts from cells, whole hearts, and infarct regions were prepared as described (26). Rabbit polyclonal primary antibodies against GLP-1R (LS-A1205, MBL International), Nrf2 (C20; Santa Cruz Biotechnology), heme-oxicgenase-1 (HO-1; Stressgen), peroxisome proliferator-activated receptor (PPAR)-β (H-74, Santa Cruz), and monoclonal antibodies against Akt, phospho-Akt (Ser473), glycogen synthase kinase (GSK)-3β, phospho-GSK-3β (Ser9), and cleaved-caspase 3 (all from Cell Signaling) as well as goat-polyclonal anti-atrial natriuretic peptide (ANP) antibodies (Santa Cruz) were used per manufacturers’ instructions. Mouse monoclonal anti-B-actin (Sigma) and anti–transcription factor I D (TIFID) (Santa Cruz) antibodies and a rabbit polyclonal anti-GAPDH (Santa Cruz) were used to evaluate the amount of protein loaded in each sample.

RT-PCR. Total RNA was isolated from hearts using TRIZOL (Invitrogen), quantified (2 μg), and treated with DNAseI. cDNA synthesis was performed by Superscript III reverse transcriptase (Invitrogen) and specific primers for the following genes: TNF-α, Gadd45a, TCA, CtG, CaCTG, G, OCC, TTC, GCT, GAC, GAA, GTC, ATG, ACG, CCA, TCT-G, and Nrf2 (F, TCT-CCT-CGTC-TGG, 5′ AAAG-AAG-AA; R, AAT-CTG-TGCTG-TGCTT-TA). PCR products were visualized on 1.5% agarose gels with ethidium bromide. GAPDH reaction product served as a loading and RT efficiency control.

Ischemia-reperfusion. Isolated hearts were prepared as previously described (27). Isolated hearts underwent a 20-min equilibration phase followed by a 40-min perfusion phase during which LV developed pressure (LVDP) was measured, and coronary flow was recorded. Ligation was generated by clamping inflow to the heart followed by reperfusion for 40 min. In some experiments, iraglutide was added to the buffer during the final 20 min of the perfusion phase (i.e., preischemia); in others, it was added to the buffer only during reperfusion (i.e., postischemia). Recovery of LVDP was measured at the end of reperfusion. These experiments were also performed using hearts isolated from mice after 1 day (acute) or 7 days (chronic) of diabetes.

Ultrasound biomicroscopy. Image acquisition and data analysis were carried out as described (28-30). Three groups of nondiabetic mice, including 8 control mice not subjected to LAD occlusion, and 15 iraglutide-treated and 15 saline-treated mice were studied on day 28 post-MI using high-frequency ultrasound imaging. Identical procedures were used to image diabetic mice (n = 5/group; LAD-ligated, n = 10-11/group).

All data are expressed as mean ± SE. Survival analysis was done by the Kaplan-Meier method (Fig. 1A and B). Student’s t test was used to compare two groups for data shown in Figs. 2–4. For analysis of echocardiographic data (Table 1) and specific time points in ischemia-reperfusion (IR) experiments (Fig. 5) and cAMP and TNF-α studies (Fig. 6), a one-way ANOVA was
FIG. 1. Liraglutide pretreatment improves outcomes after MI in mice. Kaplan-Meier survival curves show survival after MI in nondiabetic mice (A); sham (n = 20), liraglutide-MI (75 µg/kg, n = 35 or 200 µg/kg, n = 60), PBS-MI (n = 60), and pair-fed mice (n = 25), P = 0.0001 for LIR 75 and 200 versus PBS; and diabetic mice (B); sham (n = 15, 5/treatment group), PBS-MI (n = 18), metformin-MI (n = 18), liraglutide-MI (75 µg/kg, n = 18). P = 0.04 for LIR 75 versus PBS. C: Frequency and timing of cardiac rupture in nondiabetic mice is shown as a percentage of total group. One-week pretreatment with liraglutide (200 or 75 µg/kg i.p. twice daily) had no significant effects on random blood glucose levels in adult nondiabetic mice (PBS: 7.6 ± 4.0 versus LIR 200: 6.3 ± 0.6 versus LIR 75: 6.1 ± 0.4 mmol/l; P = 0.72). Blood glucose levels in diabetic mice are shown in supplemental Table 1 (available in the online appendix).

RESULTS
Liraglutide increased survival in mice post-MI. Immediate perioperative mortality (within 24 h of LAD ligation) was 8.3% in PBS- (n = 85) and 5% in LIR 200–treated (n = 60) mice (P = 0.43) with no deaths in the sham-operated animals (n = 20). By day 28 post-MI, LIR 200–treated mice exhibited reduced mortality compared with PBS-treated controls (12 of 60 versus 46 of 60; P = 0.0001) (Fig. 1A). Because mice treated with LIR 200 also exhibited weight loss compared with PBS-treated controls (−1.65 ± 0.05 versus +0.72 ± 0.02 g; P = 0.0001), we carried out additional experiments to determine whether the effects of LIR on survival post-MI were dependent on weight loss. A separate group of mice was pair-fed to achieve weight loss comparable to that of animals receiving LIR 200 for 7 days;
Liraglutide reduced infarct expansion post-MI. Cardiac rupture is known to occur more frequently with larger infarcts (30) and is believed to manifest an imbalance between inflammatory and fibrotic responses as well humoral factors acting on the infarct (31,32). To explore these possibilities in more detail, we first analyzed H&E-defined infarct size at day 28 post-MI in nondiabetic mice. Liraglutide (LIR 200) significantly reduced infarct size compared with PBS-treated mice (20.9 ± 1.7 versus 28.8 ± 3.3; percent total LV circumference, *P = 0.023*) (Fig. 2). Furthermore, cardiac hypertrophy, as manifested by heart weight/body weight (HW/BW) ratio, was significantly reduced in LIR 200–treated mice (Fig. 2). To determine if these results partly reflected survivor bias, we also examined TTC-defined infarct size at day 2 post-MI. This analysis revealed no significant difference in infarct size between LIR 200– treated mice (n = 14) and PBS-treated (n = 15) groups (40.2 ± 4.2 versus 39.3 ± 3.8; *P = 0.86). Despite significantly higher survival in liraglutide-treated diabetic mice (Fig. 1B), no differences were observed in either infarct size or HW/BW ratios in diabetic animals at day 28 post-MI (data not shown).

Liraglutide activates cardioprotective signaling pathways in the heart. To determine the mechanisms underlying liraglutide-induced improvements in survival and infarct remodeling post-MI, we studied the expression of selected genes and proteins known to modulate cardiomyocyte survival. LIR 200 administered twice daily for 7 days to normal healthy mice (without MI) increased phosphorylation of the prosurvival kinase Akt (pAkt/Akt: 2.10 ± 0.01-fold over control, *P = 0.002*) (Fig. 3A). Similarly, liraglutide increased phosphorylation and thereby reduced the activity of GSK3β, a known Akt substrate, and increased levels of the nuclear receptor PPARβ/δ and the redox-sensitive basic leucine zipper transcription factor Nrf2. Liraglutide also increased mRNA and protein levels of HO-1 (Fig. 3A), a protein strongly implicated in cardioprotection in response to ischemic injury (33). To assess the importance of the known GLP-1R for the actions of liraglutide, we administered LIR 75 for an identical 7-day treatment period in mice with genetic absence of a functional GLP-1R and littermate controls. Liraglutide increased phosphorylation of Akt and GSK3β in both wild-type (Fig. 3B) and Glp1r+/+ littermate controls (Fig. 3C), but not in Glp1r−/− mice (Fig. 3D).

To assess whether the effects of liraglutide remained detectable after cessation of liraglutide therapy and before the peak incidence of mortality post-MI (which occurred on day 5; Fig. 1A), we examined the hearts of liraglutide- and PBS-treated controls 4 days post-MI (i.e., 4 days after the final dose of liraglutide or PBS). The HW/BW ratio was reduced in liraglutide-treated mice (5.53 ± 0.14 versus 5.83 ± 0.15 mg/g, *P = 0.03*) at day 4, and levels of phosphorylated Akt were significantly higher in the infarct area of hearts from liraglutide-treated mice (Fig. 4). Similarly, liraglutide pretreatment was associated with increased GSK phosphorylation at Ser 9 and a significant reduction in levels of cleaved caspase-3 and ANP (Fig. 4). Quantitative gelatin zymography showed a significant decrease in MMP-9 activity in hearts from liraglutide-treated mice (Fig. 4). These data demonstrate a persistent effect of liraglutide pretreatment on cardiac prosurvival and remodeling pathways detectable both before (Fig. 3) and after (Fig. 4) induction of ischemic injury.
Liraglutide-treated mice exhibit improved cardiac performance. The results of cardiac ultrasound microscopy performed 4 weeks after LAD ligation or sham surgery in nondiabetic mice are shown in Table 1. After experimental MI, measures of systolic function such as cardiac output and stroke volume were significantly increased in liraglutide-treated mice. Measures of diastolic function such as mitral inflow velocities (E/A ratio) were also improved in liraglutide-treated mice and LV dilatation in the liraglutide-treated group was less severe than in PBS-treated control mice (Table 1). In contrast, although liraglutide-treated diabetic mice exhibited a significant
LIRAGLUTIDE ACTIVATES CYOTOPROTECTIVE PATHWAYS

FIG. 4. Effects of liraglutide pretreatment on cardioprotective signaling pathways after MI in mice. Liraglutide pretreatment for 7 days has persistent cardioprotective effects detectable 4 days post-MI as indicated by representative Western blots and corresponding densitometric quantification (n = 6/group) of fold changes in phosphorylation of Akt and GSK3β, cleavage of caspase-3, and expression of ANP and activity of MMP-9 by zymography in liraglutide- versus PBS-treated mice. Data shown are means ± SE; *P < 0.05.

increase in cardiac output in the absence of experimental MI, no consistent differences in echocardiographic parameters were detected in diabetic mice treated with liraglutide versus metformin at day 28 post-MI (data not shown).

Liraglutide treatment in vivo prevented ischemia-reperfusion injury of isolated hearts ex vivo. To determine whether liraglutide exhibits rapid cardioprotective actions in the isolated mouse heart ex vivo, we examined the effects of acute liraglutide administration in the isolated perfused mouse heart. Direct infusions of liraglutide immediately before and postischemia did not improve functional recovery after ischemia-reperfusion (I/R) injury in the isolated mouse heart (Fig. 5A). In contrast, pretreatment of normal healthy mice with liraglutide (200 μg/kg b.i.d.) in vivo for 1 or 7 days before heart isolation enhanced recovery of LVDP after I/R relative to untreated controls (1 day: 41.54 ± 1.5, n = 4; 7 days: 38.31 ± 0.6 mmHg, n = 5; untreated: 28.24 ± 1.8 mmHg, n = 5; P < 0.01, Fig. 5B). These results imply that liraglutide-induced cardioprotection may require a minimum dose or pretreatment period for the activation of a cardiac gene and protein expression profile and/or may be indirect, reflecting the consequences of GLP-1R activation in noncardiac tissues.

Liraglutide induces cAMP and reduces apoptosis in neonatal mouse cardiomyocytes. We next examined whether liraglutide exerts direct actions on mouse cardiomyocytes. Liraglutide (100 nM) significantly increased cAMP formation in mouse cardiomyocytes (P < 0.0001) in a GLP-1R-dependent manner, because cAMP stimulation was abolished by the GLP-1R antagonist Ex9-39 (Fig. 6A).

To determine whether liraglutide directly modulates cardiomyocyte survival, we examined the effects of liraglutide in TNF-α-treated neonatal cardiomyocytes. Liraglutide dose-dependently reduced TNF-α-induced activation of caspase 3 in cardiomyocytes in vitro. Furthermore, the protective effect of liraglutide was completely abolished after coinubcation of cells with Ex9-39 (Fig. 6B).

DISCUSSION

In the present study, we demonstrate that liraglutide administration induced changes in the expression of cardioprotective proteins in the normal nonatherosclerotic murine heart characterized by phosphorylation of Akt and GSK3β and increased expression of Nfr2, PPAR-β/δ, and HO-1. These changes were associated with improved survival of mice after experimental ischemia despite cessation of liraglutide therapy. These findings, taken together with the results of echocardiography, demonstrate that a brief 7-day period of liraglutide pretreatment leads to improvements in cardiomyocyte survival and sustained improvement in cardiac function that remain detectable even 4 weeks after cessation of liraglutide and induction of experimental MI.

TABLE 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Sham</th>
<th>MI-placebo</th>
<th>MI-liraglutide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>27.9 ± 0.3</td>
<td>29.5 ± 0.4</td>
<td>29.3 ± 0.5</td>
</tr>
<tr>
<td>Aortic flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>393 ± 12</td>
<td>451 ± 18</td>
<td>435 ± 12</td>
</tr>
<tr>
<td>Peak velocity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(cm/s)</td>
<td>86.3 ± 2.2</td>
<td>68.7 ± 2.7*</td>
<td>80.3 ± 3.2†</td>
</tr>
<tr>
<td>VTI (cm)</td>
<td>3.03 ± 0.08</td>
<td>2.06 ± 0.13*</td>
<td>2.61 ± 0.12‡</td>
</tr>
<tr>
<td>AO diameter (mm)</td>
<td>1.15 ± 0.02</td>
<td>1.15 ± 0.02</td>
<td>1.19 ± 0.01</td>
</tr>
<tr>
<td>LV SV (µl)</td>
<td>32.4 ± 1.5</td>
<td>22.1 ± 1.2*</td>
<td>28.8 ± 1.4‡</td>
</tr>
<tr>
<td>CO (ml/min)</td>
<td>12.3 ± 0.5</td>
<td>9.7 ± 0.6*</td>
<td>12.4 ± 0.6†</td>
</tr>
<tr>
<td>Mitral flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>413 ± 11</td>
<td>434 ± 14</td>
<td>424 ± 9</td>
</tr>
<tr>
<td>Peak E velocity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(cm/s)</td>
<td>71.8 ± 1.9</td>
<td>59.0 ± 3.6*</td>
<td>59.9 ± 2.2‡</td>
</tr>
<tr>
<td>Peak A velocity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(cm/s)</td>
<td>47.0 ± 1.5</td>
<td>39.8 ± 3.5*</td>
<td>43.6 ± 2.0‡</td>
</tr>
<tr>
<td>Peak E/A ratio</td>
<td>1.54 ± 0.04</td>
<td>2.54 ± 0.44*</td>
<td>1.40 ± 0.06†</td>
</tr>
<tr>
<td>LV chamber</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dimensions by M mode</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>417 ± 10</td>
<td>442 ± 17</td>
<td>441 ± 15</td>
</tr>
<tr>
<td>LV EDD (mm)</td>
<td>43.3 ± 0.05</td>
<td>6.12 ± 0.23*</td>
<td>5.52 ± 0.09†</td>
</tr>
<tr>
<td>LV ESD (mm)</td>
<td>33.3 ± 0.08</td>
<td>5.73 ± 0.30*</td>
<td>5.02 ± 0.14‡</td>
</tr>
<tr>
<td>LV FS (%)</td>
<td>23.0 ± 1.2</td>
<td>7.0 ± 1.5*</td>
<td>9.2 ± 1.3†</td>
</tr>
</tbody>
</table>

Data are means ± SE. In mitral inflow, the peak E velocity represents the maximal velocity of the early diastolic wave caused by active LV relaxation. The peak A velocity represents the maximal velocity caused by left atrial contraction in late diastole. *Difference (P < 0.05) with the corresponding value in the sham controls. †Difference (P < 0.05) with the corresponding value in the placebo (PBS)-treated controls. AO, aortic orifice; CO, cardiac output; FS, fractional shortening; SV, stroke volume; EDD, end-diastolic diameter; ESD, end-systolic diameter; VTI, velocity-time integral of Doppler flow waveform.

980 DIABETES, VOL. 58, APRIL 2009
The beneficial effects of liraglutide were independent of weight loss, because a lower dose of liraglutide (75 μg/kg) that did not produce weight loss also protected the heart and increased survival to a greater extent than that observed with the higher 200 μg/kg liraglutide dose. The weight loss observed with higher pharmacological doses of GLP-1R agonists is not required for the beneficial effects of these agents on cardiovascular function (2).

Although the mechanisms underlying the reduced cardiac rupture and improved survival remain incompletely understood, notable findings from our studies include the modulation of putative mediators (Akt, GSK3β, HO-1, PPAR-β/δ, and Nrf2) known to be important for cardiomyocyte survival (34–38). We observed reduced levels of MMP-9 and cleaved caspase 3 in the infarct region of liraglutide-treated mice at day 4 post-MI. These findings are reminiscent of observations made in studies of the effects of GLP-1 on survival of β-cells and neurons, in which GLP-1R activation leads to inhibition of caspase activation and increased cytoprotection (39,40).

Functional assessment with echocardiography showed that LV systolic function remained improved even weeks after the last dose of liraglutide. We observed significantly less dilatation of the left ventricle of liraglutide-treated mice. These findings are consistent with preclinical data demonstrating that GLP-1R agonists improve LV function in rodent and canine models of experimental cardiac dysfunction (8,9,11–13,41). The sustained benefits of transient liraglutide therapy that persisted for weeks after cessation of therapy is consistent with studies demonstrating that a 72-h infusion of GLP-1 in human subjects after MI produces sustained improvements in cardiovascular function that remained detectable even months after cessation of GLP-1 administration (14).

An unexpected finding was the observation that liraglutide, unlike native GLP-1 or GLP-129–39 (3), was not effective in directly improving LV pressure, or recovery of
LV pressure after I/R injury, when administered either immediately before induction of ischemia or during the reperfusion phase to isolated hearts ex vivo. In contrast, administration of lixivatide in vivo for as little as 1 day (two injections) before ischemia was sufficient to confer a cardioprotective benefit in subsequent I/R experiments. Our findings raise the possibility that the cardioprotective actions of lixivatide are complex and may require a specific minimum dose or defined time period for induction of a protective gene/protein profile that promotes resistance to cardiomyocyte injury. Alternatively, the cardioprotective actions of lixivatide observed in vivo may be partly indirect, mediated perhaps through neural, hormonal, or metabolic factors. This latter possibility contrasts with findings demonstrating direct protection by native GLP-1 in I/R studies (9,10,42).

Recent studies have implicated a role for the metabolite GLP-1(9–36) as a cardioactive peptide with inotropic effects in dogs with heart failure (41). The GLP-1 metabolite, GLP-1(9–36) also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1-related peptides on the ischemic heart. Lixivatide is relatively resistant to cleavage by DPP-4 and contains two amino acid modifications, a substitution and an addition, together with a fatty acid side chain. Whether lixivatide is metabolized to a peptide with GLP-1(9–36)-like activity remains unclear. The observation that lixivatide fails to induce the phosphorylation of Akt and GSK3β in the GIP1 receptor–heart, together with the demonstration that lixivatide increased cAMP and reduced apoptosis in cardiomyocyte cultures in a GLP-1-dependent manner, strongly implicates the known GLP-1R as a critical mediator of lixivatide action in the murine heart.

Drugs acting on the GLP-1R axis have been approved for the treatment of diabetes and have the added benefits of reducing appetite and body weight and, in some instances, blood pressure, leading to improvement of cardiovascular risk factors (43,44). Given the experimental data presented here and elsewhere (8,9,13,16), the possibility that these agents may have beneficial effects on cardiovascular outcomes of patients with diabetes, independent of improvements in blood pressure and blood glucose, requires further study.

ACKNOWLEDGMENTS

These studies were supported in part by grants from the Heart and Stroke Foundation of Ontario (NA5926), CIHR Grant IRO 80668, and Novo Nordisk.

L.L.B. has served as a panel member and/or received a speaker’s honorarium for symposia sponsored by Novo Nordisk, Merck Frosst, and GlaxoSmithKline. M.H. has served as a consultant to sanofi-aventis and Merck & Co. D.D. has served as an advisor or consultant to Amylin Pharmaceuticals, Arena, Arisaph Pharmaceuticals, ConjuChem, Eli Lilly, Emisphere Technologies, GlaxoSmithKline, Genmark Pharmaceuticals, Hoffmann LaRoche, Isis Pharmaceuticals, Mannkind, Merck Research Laboratories, Metabolix, Novartis Pharmaceuticals, Novo Nordisk, Phenomix, Takeda, and Transition Pharmaceuticals. No other potential conflicts of interest relevant to this article were reported.

Parts of this study were presented in abstract form at the 68th Scientific Sessions of the American Diabetes Association, San Francisco, California, 6–10 June 2008.

REFERENCES


10. Bose AK, Mocanu MM, Carr RD, Yellen DM: Glucagon-like peptide 1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated heart model. Cardioren Drugs Ther 10:9–11, 2005


